MIF maintains the tumorigenic capacity of brain tumor-initiating cells by directly inhibiting p53

Raita Fukaya, Shigeki Ota, Tomonori Yaguchi, Yumi Matsuzaki, Eiji Sugihara, Hideyuki Okano, Hideyuki Saya, Yutaka Kawakami, Takeshi Kawase, Kazunari Yoshida, Masahiro Toda

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Tumor-initiating cells thought to drive brain cancer are embedded in a complex heterogeneous histology. In this study, we isolated primary cells from 21 human brain tumor specimens to establish cell lines with high tumorigenic potential and to identify the molecules enabling this capability. The morphology, sphereforming ability upon expansion, and differentiation potential of all cell lines were indistinguishable in vitro. However, testing for tumorigenicity revealed two distinct cell types, brain tumor-initiating cells (BTIC) and non-BTIC. We found that macrophage migration inhibitory factor (MIF) was highly expressed in BTIC compared with non-BTIC. MIF bound directly to both wild-type and mutant p53 but regulated p53-dependent cell growth by different mechanisms, depending on glioma cell line and p53 status. MIF physically interacted with wild-type p53 in the nucleus and inhibited its transcription-dependent functions. In contrast, MIF bound to mutant p53 in the cytoplasm and abrogated transcription-independent induction of apoptosis. Furthermore, MIF knockdown inhibited BTIC-induced tumor formation in a mouse xenograft model, leading to increased overall survival. Collectively, our findings suggest that MIF regulates BTIC function through direct, intracellular inhibition of p53, shedding light on the molecular mechanisms underlying the tumorigenicity of certain malignant brain cells.

Original languageEnglish
Pages (from-to)2813-2823
Number of pages11
JournalCancer Research
Volume76
Issue number9
DOIs
Publication statusPublished - 2016 May 1

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this